CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
June 2015—Rosetta Genomics has agreed to acquire CynoGen, which does business as PersonalizeDx, from Prelude Corp., a Fjord Ventures portfolio company. The acquisition is contingent upon the closing of Prelude’s purchase of PersonalizeDx from a third party.
PersonalizeDx is a rapidly growing molecular diagnostics and services company serving community-based pathologists, urologists, oncologists, and reference laboratories across the U.S. Through this transaction, Rosetta Genomics will gain proprietary tests in prostate, bladder, and lung cancer, as well as commercial and laboratory operations capabilities and a high-complexity CLIA laboratory in Lake Forest, Calif.
The purchase price includes $2 million in cash, 500,000 ordinary shares of Rosetta Genomics, some specified assets, and services that Rosetta will provide to Prelude. In connection with this transaction, Rosetta will gain rights to market Prelude’s novel assay for ductal carcinoma in situ.
Rosetta Genomics, 215-382-9000